Horenshtein Hadar Mirit 4

What Happened
Mirit Horenshtein, CFO and Secretary of Silexion Therapeutics Corp (SLXN), was granted 7,500 fully vested restricted share units (RSUs) on June 4, 2026; the RSUs were immediately settled for 7,500 ordinary shares. The Form 4 reports the acquisition price as $0.00, reflecting that these were awards settled into shares rather than a cash purchase.

Key Details

• Transaction date: 2026-06-04 (reported on Form 4 filed 2026-06-08).
• Transaction type/code: Award/Grant (A) — 7,500 shares acquired at $0.00 (RSU settlement).
• Shares owned after transaction: 12,515 ordinary shares (5,015 prior to the grant after a 1-for-10 reverse split, plus 7,500 from this grant).
• Approval/authority: Grant approved by the issuer’s board of directors (per footnote).
• Timeliness: Form 4 filed within the SEC two-business-day window (not late).

Context

• These were RSUs that vested and were immediately converted into shares (not an option exercise or open-market purchase). No cash was paid by the insider for these shares.
• Awards like this are typically compensation for service; they do not, by themselves, indicate a buy or sell signal.